The impact of hepatitis C virus outside the liver: Evidence from Asia

Liver International

Volumn 37, Issue 2, 2017, Pages 159-172

  Younossi, Zobair M ^a,b   Tanaka, Atsushi ^c   Eguchi, Yuichiro ^d   Lim, Young Suk ^e   Yu, Ming Lung ^f   Kawada, Norifumi ^g   Dan, Yock Young ^h   Brooks Rooney, Craig ⁱ   Negro, Francesco ^j   Mondelli, Mario U ^k  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAGA UNIVERSITY HOSPITAL   (Japan)

^e Asan Medical Center   (South Korea)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ Monsanto Singapore CO (Pte) Ltd   (Singapore)

^j UNIVERSITY HOSPITAL   (Switzerland)

^k UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

cost effectiveness; health related quality of life; hepatitis C; patient reported outcomes; work productivity

Indexed keywords

ASIA; CHRONIC HEPATITIS C; CLINICAL PRACTICE; ECONOMIC ASPECT; END STAGE LIVER DISEASE; FATIGUE; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER; LIVER CELL CARCINOMA; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; COMBINATION DRUG THERAPY; COMPLICATION; COST; HEPACIVIRUS; LIVER CIRRHOSIS; LIVER TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIROLOGY;

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE;

EID: 85000786824     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13272     Document Type: Review

References (105)

1. Harris M, Ward E, Gore C. Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. J Viral Hepatitis. 2016;23:479–486.
2. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 2015;149:1471–1482.e1475; quiz e1417-1478.
3. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016a;150:1599–1608.
4. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497–520.
5. Pawlotsky JM. Hepatitis C virus: from discovery to eradication in 40 years? Clin Microbiol Infect. 2011;17:105–106.
6. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777–782.
7. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2005;51:31–46.
8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.
9. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–S50.
10. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127(5 Suppl 1):S17–S26.
11. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014;60:1767–1775.
12. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan Intervirology 2010;53:39–43.
13. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27:291–299.
14. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174–181.
15. Imazeki F, Yokosuka O, Fukai K, et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005;25:772–778.
16. Dohmen K, Kawano A, Takahashi K, et al. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterology. 2013;60:2034–2038.
17. Masaki N, Yamagiwa Y, Shimbo T, et al. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health. 2015;15:1.
18. Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial disparities in treatment rates for chronic hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States. Medicine. 2016;95:e3719.
19. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350–1356.
20. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(Pt 1):329–337.
21. Tseng CW, Chang TT, Tzeng SJ, et al. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging. 2016;11:327–334.
22. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730–740.
23. Ikezaki H, Nomura H, Furusyo N, et al. Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatol Res. 2016;46:E174–E180.
24. Asahina Y, Izumi N, Hiromitsu K, et al. JSH guidelines for the management of hepatitis C virus infection: a 2016 update for genotype 1 and 2. Hepatol Res. 2016;46:129–165.
25. Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016;65:719–726.
26. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016;65:861–862.
27. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Therap Adv Infect Dis. 2016;3:3–14.
28. Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–1360.
29. Nagao Y, Tanaka J, Nakanishi T, et al. High incidence of extrahepatic manifestations in an HCV hyperendemic area. Hepatol Res. 2002;22:27–36.
30. Lee M-H, Yang H-I, Lu S-N, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469–477.
31. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 2016b;111:808–816.
32. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74:65132–65133.
33. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011;9:86.
34. Martin L, Younossi Z. Health-related quality of life (HRQL) in chronic liver disease. Dig Liver Dis. 2005;37:819–820.
35. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405–413; discussion 415-420.
36. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717–1727.
37. Younossi Z, Loria A, Eschiek C, Gerber L, Kallman J. The Chronic Liver Disease Questionnaire-Hepatitis C (CLDQ-HCV): A sensitive and valid health related quality of life instrument. Paper presented at: American Association for the Study of Liver Disease Annual Meeting 2012.
38. Fukuhara S, Ikegami N, Torrance GW, Nishimura S, Drummond M, Schubert F. The development and use of quality-of-life measures to evaluate health outcomes in Japan. Pharmacoeconomics. 2002;20(Suppl 2):17–23.
39. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037–1044.
40. Tanaka A, Kikuchi K, Miura R, et al. Validation of the Japanese version of the Chronic Liver Disease Questionnaire for the assessment of health-related quality of life in patients with chronic viral hepatitis. Hepatol Res. 2016;46:E45–E50.
41. Kim J, Kim K. Gender differences in health-related quality of life of Korean patients with chronic obstructive lung disease. Public Health Nurs 2015;32:191–200.
42. Song HJ, Lee EK, Kwon JW. Gender differences in the impact of obesity on health-related quality of life. Asia Pac J Public Health. 2016;28:146–156.
43. Quinten C, Coens C, Ghislain I, et al. The effects of age on health-related quality of life in cancer populations: a pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer 2015;51:2808–2819.
44. Kalyva E, Abdul-Rasoul M, Kehl D, Barkai L, Lukacs A. A cross-cultural study on perceived health-related quality of life in children and adolescents with type 1 diabetes mellitus. J Diabetes Complications. 2016;30:482–487.
45. Dibonaventura MD, Yuan Y, Lescrauwaet B, et al. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS ONE. 2014;9:e86070.
46. Marcellin F, Préau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007;8:320–327.
47. Sarkar S, Jiang Z, Evon D, Wahed A, Hoofnagle J. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57:946–952.
48. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936–939.
49. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
50. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016c;65:33–39.
51. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014;12:1349–1359.e1313.
52. Gosselin E, Lemyre L, Corneil W. Presenteeism and absenteeism: differentiated understanding of related phenomena. J Occup Health Psychol. 2013;18:75–86.
53. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
54. Samp JC, Perry R, Piercy J, Wood R, Baran RW. Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clin Res Hepatol Gastroenterol. 2015;39:307–314.
55. Scott J, Gilles L, Fu M, et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. J Viral Hepatitis. 2015;22:639–650.
56. Vietri J, Otsubo T, Montgomery W, Tsuji T, Harada E. The incremental burden of pain in patients with depression: results of a Japanese survey. BMC Psychiatry. 2015;15:1.
57. Strauss E, Porto-Ferreira FA, de Almeida-Neto C, Teixeira MC. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol. 2014;38:40–45.
58. Fábregas BC, de Ávila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL. Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. Braz J Infect Dis. 2013;17:633–639.
59. Sobhonslidsuk A, Silpakit C, Kongsakon R, Satitpornkul P, Sripetch C, Khanthavit A. Factors influencing health-related quality of life in chronic liver disease. World J Gastroenterol. 2006;12:7786–7791.
60. Matsushita H, Ikeda F, Iwasaki Y, et al. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol. 2014;29:337–343.
61. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci. 2003;48:1622–1626.
62. Jara M, Bednarsch J, Malinowski M, et al. Predictors of quality of life in patients evaluated for liver transplantation. Clin Transplant. 2014;28:1331–1338.
63. Chang SC, Yang SS, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health Qual Life Outcomes. 2014;12:97.
64. Younossi ZM, Stepanova M, Mizokami M, Omata M, Hunt S. Higher Quality of Life Gains in Japanese Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir. Tokyo: Asian Pacific Association for the Study of the Liver; 2016d.
65. Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15(1 Suppl):S65–S71.
66. Kumada H, daCosta DM, Yuan Y, et al. The patient-related burden of pegylated-interferon-α therapy and adverse events among patients with viral hepatitis C in Japan. Value Health Reg Issues 2014;3:50–58.
67. Younossi ZM, Stepanova M, Omata M, Mizokami M, Hunt S. Quality of Life of Japanese Patients with Chronic Hepatitis C Treated with Ledipasvir and Sofosbuvir. Tokyo: Asian Pacific Association for the Study of the Liver; 2016e.
68. Younossi Z, Stepanova M, Omata M, Mizokami M, Nader F, Hunt S. Fatigue in Japanese patients with chronic hepatitis C treated with Ledipasvir and Sofosbuvir with or without Ribavirin. Value Health. 2016f;19:A316–A317.
69. Smith MA, Chan J, Mohammad RA. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann Pharmacother. 2015;49:343–350.
70. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.
71. Mandorfer M, Payer BA, Scheiner B, et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int. 2014;34:69–77.
72. Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther. 2013;38:124–133.
73. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104:2439–2448.
74. Adinolfi LE, Nevola R, Lus G, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21:2269–2280.
75. Senzolo M, Schiff S, D'Aloiso CM, et al. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol. 2011;17:3369–3374.
76. Nordon C, Karcher H, Groenwold RH, et al. The “Efficacy-Effectiveness Gap”: historical background and current conceptualization. Value Health. 2016;19:75–81.
77. Vo KP, Vutien P, Akiyama MJ, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with Pegylated interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci. 2015;60:1045–1051.
78. Niederau C, Mauss S, Schober A, et al. Predictive factors for sustained virological response after treatment with pegylated interferon alpha-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS ONE. 2014;9:e107592.
79. Chen TM, Huang PT, Wen CF, Tung JN, Chow KC, Chen YP. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. J Viral Hepatitis. 2011;18:119–128.
80. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepatitis. 2005;12:91–95.
81. Bonner JE, Esserman DA, Golin CE, Evon DM. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol. 2015;49:76–83.
82. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol. 2010;8:972–978.
83. Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine. 2015;94:e690.
84. Boccuzzi SJ. Indirect health care costs. In: Weintraub WS, ed. Cardiovascular Health Care Economics. New York, NY: Humana Presss; 2003:63–79.
85. Kieran JA, Norris S, O'Leary A, et al. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infect Dis. 2015;15:471.
86. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531–546.
87. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–419.
88. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61:157–168.
89. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544–563.
90. Deuffic-Burban S, Obach D, Canva V, et al. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepatitis 2016;23:767–779.
91. Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics 2016a;34:551–567.
92. Gissel C, Gotz G, Mahlich J, Repp H. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany–an application of the efficiency frontier approach. BMC Infect Dis. 2015;15:297.
93. Igarashi A, Guerra I, Marié L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:11–21.
94. Igarashi A, Tang W, Cure S, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:1–10.
95. Zhao YJ, Khoo AL, Lin L, et al. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol 2016;31:1628–1637.
96. McEwan P, Ward T, Webster S, et al. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res 2015;46:423–433.
97. Chhatwal J, He T, Hur C, Lopez-Olivo M. Cost-effectiveness of direct-acting antivirals for hepatitis C treatment: a systematic review of 227 analysis. Barcelona: The International Liver Congress; 2016b.
98. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 2016;65:727–733.
99. Pol S. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 2016;65:734–740.
100. Younossi ZM, Chan HYL, Dan YY, et al. Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Chronic Hepatitis C patients in Asia. Tokyo: Asian Pacific Association for the Study of the Liver; 2016 g.
101. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The Value of Cure Associated with Treating Treatment-naive (TN) Chronic Hepatitis C (CH-C) Genotype 1 (GT1): Are the New All Oral Regimens a Good Value to Society? Liver Int. 2016; doi: 10.1111/liv.13298 [Epub ahead of print].
102. Medical Outcomes Study: 36-Item Short Form Survey Scoring Instructions. http://www.rand.org/health/surveys_tools/mos/mos_core_36item_scoring.html. Accessed May 06, 2016.
103. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295–300.
104. Shiell A, Donaldson C, Mitton C, Currie G. Health economic evaluation. J Epidemiol Community Health. 2002;56:85–88.
105. Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value Health. 2016;19:544–551.